Skip to main content

Table 3 Treatment outcomes

From: Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

 

All patients (n = 30)

Castrate-resistant (n = 11)

Castrate-sensitive (n = 19)

p-value

Biochemical/clinical failure

16 (53%)

10 (91%)

6 (32%)

0.008

Metastatic progression

10 (63%)

7 (64%)

3 (16%)

0.007

Median time to failure, months (range)

16 (6–38)

13 (6–28)

23 (10–38)

 

Median RFS, months (range)

22 (6–43)

13 (6–28)

26 (10–43)

 < 0.001

2 and 3-year RFS

60% and 53%

18% and 9%

84% and 79%

 < 0.001

2 and 3-year MFS

 

36% and 27%

90% and 90%

0.001

  1. RFS, recurrence-free survival; MFS, metastasis-free survival